|
Agent Type:
|
Synthetic; Small molecule; Direct acting;
|
|
Spectrum of activity:
|
Gram-positive & Gram-negative
|
|
Mechanism of action:
|
Membrane-active agent. Disrupts integrity of cell membrane and inhibits NDM
|
|
Target Pathogen:
|
Active against Staphylococcus aureus, Escherichia coli, and other NDM-producing strains
|
|
Description:
|
Synthetic compound derived from nitroxoline (5-nitro-8-hydroxyquinoline) scaffold; shows synergistic effect with meropenem against NDM-1 producing strains; cytotoxic (IC50) and haemolytic activity only at concentrations >12xMIC50
|
|
Institute where first reported:
|
Asieris Pharmaceuticals
|
|
Year first mentioned:
|
2024
|
|
Highest developmental phase:
|
Phase 1 (to begin in Australia in 2024)
|
|
Development status:
|
Active as of 2024
|